OtherPublished 23 Jul 2016
Oral iron therapies in development for iron deficiency in chronic kidney disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Iron supplementation remains a key component of anemia management in chronic kidney disease, which is associated with functional as well as absolute iron deficiency. There remains concern about the risks of intravenous iron, but oral iron supplements are poorly absorbed due to hepcidin-induced absorption block and are associated with gastrointestinal intolerance. Newer iron preparations with greater bioavailability and better tolerability than ferrous sulfate, or other agents which bypass the gastrointestinal block of iron absorption, offer the potential for normalizing iron stores without the need for intravenous iron. We review the current status of available iron supplements and summarize the recent clinical trial evidence for their use, with a particular focus on new oral supplements and those currently in development.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “David William Mudge”
- BylineArticles whose byline prints “David Wayne Johnson”